Transdermal Drug Delivery
Unlocking New Therapeutic Pathways
While traditional transdermal systems remain confined to small molecules, Biotts is building a new generation of transdermal drug candidates. We leverage our MTC-Y™ carrier platform to reformulate proven Active Pharmaceutical Ingredients (APIs) – including selected peptides – into patient-friendly transdermal patches (TTS) and topical formulations with controlled, sustained release profiles. Our platform enables both systemic delivery for metabolic therapies and targeted local delivery for pain management.
The Strategic Advantage
Our approach creates value on two fronts:
- For Patients: Transdermal delivery is designed to provide a non-invasive alternative to injections and oral dosing, with more consistent drug exposure over time. This approach reduces concentration fluctuations, can bypass first-pass metabolism associated with oral dosing, and may support improved treatment adherence.
- For Partners: We offer a pragmatic pathway for lifecycle management. Reformulating established molecules into novel transdermal products creates opportunities for new intellectual property and product differentiation in competitive therapeutic segments.
Core Therapeutic Areas
Our development pipeline focuses on indications where controlled delivery offers meaningful clinical potential:
- Metabolic & Diabetes Management
Our portfolio includes a transdermal SGLT2 inhibitor (Phase 1 clinical successfully completed) and formulations of insulin and GLP-1 receptor agonists. These candidates are designed to deliver peptide therapeutics through the skin, with preclinical models demonstrating sustained therapeutic concentrations in a needle-free format.
- Pain & Inflammation
For acute and chronic pain applications, we have developed transdermal formulations engineered for targeted local delivery. Preclinical comparative studies show higher tissue concentrations at the site of action versus reference topical products, with a lower systemic exposure signal and supportive local tolerability in preclinical assessments.
Each program is presented with study design, pharmacokinetic data, and development conclusions.